TEV-'287 / MODAG, Teva - LARVOL DELTA

TEV-56287 MITIGATES ALPHA-SYNUCLEIN PATHOLOGY IN A DOUBLE-HIT MOUSE MODEL OF PARKINSON'S DISEASE (ADPD 2026) - "Our findings support the disease-modifying potential of TEV-56287 by targeting alpha-synuclein aggregation. TEV-56287 may offer a promising therapeutic approach to slow PD progression and improve motor function."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease